First Results from the PEARL Trial of Rapamycin – Fight Aging!

The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial, largely crowdfunded by Lifespan.io, has revealed its first results. Rapamycin, a calorie restriction mimetic drug, showed promising improvements in health measures over 48 weeks. The study included 115 participants receiving varying doses of rapamycin or placebo, with the 10 mg group demonstrating significant benefits in healthspan metrics. Despite the lower bioavailability of compounded rapamycin used in the trial, results suggest potential for rapamycin in reducing age-related risks and mortality. Further research with larger cohorts and longer observation periods is recommended to confirm these findings.